Enhancement updates provide short alerts to new, fixed or improved Connect Care functions...
- Rifaximin BPAs
As of March 12, 2024, two new cirrhosis-related Best Practice Advisories (BPAs) have been implemented in Connect Care. Readmission to hospital for patients with cirrhosis is common and, with the added comorbidity of hepatic encephalopathy, the patient’s likelihood of requiring readmission increases. To reduce the risk of readmissions for hospitalized patients taking lactulose for hepatic encephalopathy, the new BPAs suggest ordering/continuing rifaximin with the second and subsequent episodes of hepatic encephalopathy or with lactulose intolerance.
- Rifaximin BPA - Upon Signing Lactulose Order: This interruptive BPA will fire for admitted patients with an active problem or encounter diagnosis of cirrhosis and/or hepatic encephalopathy, if the prescriber is signing an order for Lactulose and Rifaximin has not been ordered.
- Rifaximin BPA - Inpatient Discharge BPA Section: This non-interruptive BPA will fire for admitted patients being discharged with an active problem or encounter diagnosis of cirrhosis and/or hepatic encephalopathy, if the patient has an active order for Rifaximin. This BPA will continue to display until acknowledged.
